stockrow
Friday 6 November 2026
Export CTMX’s income statement to Excel — free account
CytomX Therapeutics, Inc.
CTMX Healthcare Biotechnology
CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024.
- Revenue
- −71.7%
- EPS
- 0.00%
- Free cash flow
- +204.1%
Quarter to September 2026, against a year earlier
2.19
0.05
+2.34%
Follow CTMX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.71 | 23.44 | 44.86 | 42.49 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(25.28) | (32.61) | (45.44) | 35.80 | |
P/B ratio |
5.93 | 2.60 | 2.72 | 2.09 | |
Price to Tangible BV |
6.02 | 2.62 | 2.73 | 2.10 | |
EV/Sales |
5.97 | 13.80 | 26.99 | 19.17 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.01) | (6.12) | (5.99) | (5.35) | |
EV/FCF |
(6.00) | (6.11) | (5.98) | (5.28) | |
Quick Ratio |
2.98 | 10.21 | 9.25 | 0.01 | |
Current Ratio |
3.09 | 10.38 | 9.36 | 7.82 | |
Net Debt/EBITDA |
4.87 | 17.21 | 13.16 | — | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.56 | 0.16 | 0.07 | 0.05 | |
Operating CF/Net income |
0.79 | 1.40 | 0.87 | (0.83) | |
Capex/Depreciation |
0.96 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,202.71% | 187.54% | 1,241.04% | 976.30% | |
Selling, General and Administrative Expense of Revenue |
1,110.11% | 104.23% | 536.04% | 516.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
223.08% | 45.88% | 181.73% | 168.42% | |
Graham Net Nets |
0.16 | 0.38 | 0.36 | 0.46 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.97%) | (8.75%) | (13.33%) | (18.38%) | |
Free Cash Flow Yield |
(12.90%) | (9.64%) | (10.06%) | (8.54%) | |
Revenue per Share |
0.00 | 0.06 | 0.01 | 0.01 | |
Operating CF per Share |
(0.17) | (0.14) | (0.08) | 0.08 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.17) | (0.14) | (0.08) | 0.07 | |
Cash per Share |
0.99 | 1.96 | 1.51 | 0.00 | |
Shareholders Equity per Share |
0.72 | 1.80 | 1.38 | 1.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.72 | 1.80 | 1.38 | 1.30 | |
Free Cash Flow |
(23.44) | (25.55) | (18.07) | 16.06 | |
Working Capital |
97.31 | 319.07 | 333.29 | 310.52 | |
Capital Expenditures |
(0.20) | — | — | (0.59) | |
Net Current Asset Value |
91.36 | 313.68 | 294.00 | 276.26 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.30 | 0.00 | 0.00 | 0.35 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.56 | 1.30 | 19.68 | 1.07 | |
Average Payables |
1.19 | 0.82 | 1.08 | 0.89 | |
Average Assets |
136.05 | 228.93 | 278.14 | 261.47 | |
Average Common Equity |
49.28 | 172.50 | 210.99 | 196.14 |
Columns are period end dates · fundamentals updated 5 Nov 2026